One dot per activity, in the year it happened. Hover for details, click to open them.
Modality:Small moleculeOligonucleotideGene therapy / editingAntibody / biologicUndisclosedRepurposingStatus:ActiveCompleted (trials)Ended (deals and investments)Discontinued (programs)Unknown
← Scroll to see all years →
| Activity typeYear indicator rule | 2006 | '07 | '08 | '09 | 2010 | '11 | '12 | '13 | '14 | 2015 | '16 | '17 | '18 | '19 | 2020 | '21 | '22 | '23 | '24 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| In-house programsfirst public evidence | |||||||||||||||||||||
| Acquired programsdeal announced | |||||||||||||||||||||
| Partnershipspartnership starts | |||||||||||||||||||||
| Discontinued programsstopped, or last public evidence | |||||||||||||||||||||
| Academic trial supporttrial starts | |||||||||||||||||||||
| Investmentsround closes | |||||||||||||||||||||
| Generic tolvaptanapproval |
Ranked by Pharma 50 position (2024 drug revenue). One dot per activity. Click a company to focus the maps on it; click a column header to sort.
Modality:Small moleculeOligonucleotideGene therapy / editingAntibody / biologicUndisclosedRepurposingStatus:ActiveCompleted (trials)Ended (deals and investments)Discontinued (programs)Unknown
← Scroll to see all columns →
| 1 | 1 | ||||||||
| 2 | 2 | ||||||||
| 3 | 6 | ||||||||
| 4 | 1 | ||||||||
| 5 | 2 | ||||||||
| 6 | 3 | ||||||||
| 7 | 6 | ||||||||
| 9 | 1 | ||||||||
| 10 | 4 | ||||||||
| 11 | 1 | ||||||||
| 12 | 4 | ||||||||
| 15 | 1 | ||||||||
| 16 | 2 | ||||||||
| 17 | 1 | ||||||||
| 18 | 1 | ||||||||
| 22 | 1 | ||||||||
| 25 | 1 | ||||||||
| 26 | 2 | ||||||||
| 27 | 5 | ||||||||
| 32 | 1 | ||||||||
| 45 | 2 |
One chip per program or activity, placed at the latest stage the asset reached. Partner, stage at deal and terms are in the chip detail.
Modality:Small moleculeOligonucleotideAntibody / biologicUndisclosedRepurposingStatus:ActiveCompleted (trials)Ended (deals and investments)Discontinued (programs)
← Scroll to see all stages →
| Activity | Preclinical | IND | Phase 1 | Phase 2 | Phase 3+ | Approved |
|---|---|---|---|---|---|---|
| In-house programs | ||||||
| Acquired programs | ||||||
| Partnerships | ||||||
| Discontinued programs | ||||||
| Academic trial support | ||||||
| Generic tolvaptan |
Equity investments by pharma or their venture arms in companies with an ADPKD program, by round. Amounts are total round size.
Modality:Small moleculeGene therapy / editingStatus:ActiveEnded (deals and investments)Unknown
← Scroll to see all rounds →
| Round | Founding & seed | Series A | Series B | Series C & later private | Round not disclosed |
|---|---|---|---|---|---|
| Pharma or venture arm → company |